173 related articles for article (PubMed ID: 22617128)
1. Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer.
Aft RL; Naughton M; Trinkaus K; Weilbaecher K
Br J Cancer; 2012 Jun; 107(1):7-11. PubMed ID: 22617128
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Knauer M; Moik M; Jakesz R; Seifert M; Taucher S; Bjelic-Radisic V; Balic M; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Selim U; Fitzal F; Hochreiner G; Wette V; Sevelda P; Ploner F; Bartsch R; Fesl C; Greil R;
Ann Oncol; 2015 Feb; 26(2):313-20. PubMed ID: 25403582
[TBL] [Abstract][Full Text] [Related]
3. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
5. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.
Jallouk AP; Paravastu S; Weilbaecher K; Aft RL
Breast Cancer Res Treat; 2021 May; 187(1):135-144. PubMed ID: 33591469
[TBL] [Abstract][Full Text] [Related]
7. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
8. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
Coleman R; Hall A; Albanell J; Hanby A; Bell R; Cameron D; Dodwell D; Marshall H; Jean-Mairet J; Tercero JC; Rojo F; Gregory W; Gomis RR
Lancet Oncol; 2017 Nov; 18(11):1543-1552. PubMed ID: 29037984
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
[TBL] [Abstract][Full Text] [Related]
10. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
Coleman R; Woodward E; Brown J; Cameron D; Bell R; Dodwell D; Keane M; Gil M; Davies C; Burkinshaw R; Houston SJ; Grieve RJ; Barrett-Lee PJ; Thorpe H
Breast Cancer Res Treat; 2011 Jun; 127(2):429-38. PubMed ID: 21394500
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study.
Wilson C; Bell R; Hinsley S; Marshall H; Brown J; Cameron D; Dodwell D; Coleman R
Eur J Cancer; 2018 May; 94():70-78. PubMed ID: 29544162
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
Ishikawa T; Akazawa K; Hasegawa Y; Tanino H; Horiguchi J; Miura D; Hayashi M; Kohno N
J Surg Res; 2017 Dec; 220():46-51. PubMed ID: 29180210
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract][Full Text] [Related]
14. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN
J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129
[TBL] [Abstract][Full Text] [Related]
15. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.
Banys M; Solomayer EF; Gebauer G; Janni W; Krawczyk N; Lueck HJ; Becker S; Huober J; Kraemer B; Wackwitz B; Hirnle P; Wallwiener D; Fehm T
BMC Cancer; 2013 Oct; 13():480. PubMed ID: 24128322
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
Zhao X; Xu X; Zhang Q; Jia Z; Sun S; Zhang J; Wang B; Wang Z; Hu X
BMC Cancer; 2011 Sep; 11():403. PubMed ID: 21936956
[TBL] [Abstract][Full Text] [Related]
17. Dosing of zoledronic acid throughout the treatment continuum in breast cancer.
Hadji P; Gnant M; Aapro M; Lipton A; Coleman R
Crit Rev Oncol Hematol; 2011 Aug; 79(2):175-88. PubMed ID: 20846875
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
19. Managing bone health with zoledronic acid: a review of randomized clinical study results.
Hadji P
Climacteric; 2011 Jun; 14(3):321-32. PubMed ID: 21182431
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.
He M; Fan W; Zhang X
J Hematol Oncol; 2013 Oct; 6(1):80. PubMed ID: 24283946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
